JMCCF yields 1775064.68% · PFE yields 6.13%● Live data
📍 JMCCF pulled ahead of the other in Year 1
Combined, JMCCF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JMCCF + PFE for your $10,000?
JAMCO Corporation manufactures and sells aircraft interiors, seats, and components in Japan. The company offers aircraft interior products, including galleys and bar counters; lavatories comprising touch-less faucets, counters, mirrors and lights, bidet systems, and touch-less flush switches; galley inserts consisting of steam ovens; and flight deck linings, consoles, and stowage, as well as seats and seat consoles. It also provides aircraft components, which includes heat exchangers and chassis for electronic equipment; aircraft engine parts, such as cooling manifolds, engine pipes, turbine shrouds, and outer transition liner products; and stringers and stiffeners for vertical tails. In addition, the company offers aircraft maintenance services for small-sized aircraft and helicopters and regional aircraft; and aircraft accessories maintenance services for system components, rescue hoists, wheels and brakes, high pressure gas cylinder, emergency evacuation slides, and cabin equipment and atmospheric observation equipment. Further, it provides nondestructive testing, welding, composites, and laser machining services. The company was formerly known as New Japan Aircraft Maintenance Co., Ltd. and changed its name to JAMCO Corporation in June 1988. JAMCO Corporation was incorporated in 1949 and is headquartered in Tachikawa, Japan.
Full JMCCF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.